Viking Therapeutics VKTX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's interest expense?
- Viking Therapeutics (VKTX) reported interest expense of $5.8M in Q1 2026.
- How has Viking Therapeutics's interest expense changed year-over-year?
- Viking Therapeutics's interest expense decreased by 41.2% year-over-year, from $9.86M to $5.8M.
- What is the long-term trend for Viking Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Viking Therapeutics's interest expense has grown at a 163.0% compound annual growth rate (CAGR), from $704K to $33.7M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.